Programs & Pipelines

Pipeline

Powered by Mito+

Programs Indications Preclinical IND Enabling Activities Phase 1 Phase 2 Global Rights
CB4211 NASH
Preclinical Phase complete
IND Enabling Activities Phase complete
Phase 1 Phase in progress
Phase 2 Phase not started
CohBar, Inc. logo
Obesity
Preclinical Phase complete
IND Enabling Activities Phase complete
Phase 1 Phase in progress
Phase 2 Phase not started
CohBar, Inc. logo
CB5138-3 IPF, Fibrotic Diseases
Preclinical Phase complete
IND Enabling Activities Phase in progress
Phase 1 Phase not started
Phase 2 Phase not started
CohBar, Inc. logo
Apelin Agonists Covid-19 ARDS, ARDS
Preclinical Phase in progress
IND Enabling Activities Phase not started
Phase 1 Phase not started
Phase 2 Phase not started
CohBar, Inc. logo
Discovery Efforts Fibrotic, Inflammatory, etc.
Preclinical Phase in progress
IND Enabling Activities Phase not started
Phase 1 Phase not started
Phase 2 Phase not started
CohBar, Inc. logo

CB5138-3 for Idiopathic Pulmonary Fibrosis and Other Fibrotic Diseases

Anti-fibrotic & Anti-inflammatory

Our second clinical candidate.

View Program

CB4211 for Nonalcoholic Steatohepatitis (NASH) and Obesity

Novel Mechanism of Action: Enhances Insulin Signaling

The first analog from our Mito+ platform to be tested in humans.

View Program

CB5064 Analogs for Acute Respiratory Distress Syndrome (ARDS)

Selectively Activates the Apelin Receptor

View Program

Discovery Efforts

Continued mining of the mitochondrial genome and development of novel analogs

View Program

Posters & White Papers

View our posters and white papers regarding our research and science.

View Publications